Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer

Official Title

Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer


To improve radiation therapy of prostate cancer, the investigators must be able to accurately identify the tumour. By using advanced functional imaging techniques available on state-of-the-art MRI scanners to clearly show the specific location of the tumour inside the prostate, the investigators can use advanced radiation therapy techniques to specifically target the tumour and control it with as few radiation therapy clinic visits as possible. This is different than current techniques which treat the whole prostate gland to the same dose, delivered over 7-8 weeks of daily radiation therapy visits. By increasing the radiation dose to the active tumour while still maintaining adequate radiation dose to the rest of the prostate, the investigators hope to better control prostate cancer and reduce complications to nearby normal tissues.

Trial Description

Primary Outcome:

  • Quality of Life as per EPIC
Secondary Outcome:
  • Quality of Life as per EPIC and SF-12
  • GU and GI Toxicity
  • Biochemical failure
  • Pathologic response
This project combines advances in functional imaging of prostate cancer and hypofractionation through stereotactic body radiation therapy (SBRT), with an aim to improve tumour control and reduce or maintain normal tissue complications. The strategy will make use of the combined effectiveness of several functional imaging approaches to identify the dominant lesion(s) within the prostate. An SBRT treatment plan will be designed which utilizes 5 fractions to treat the entire prostate gland with an additional boost to the dominant lesion. The lower dose to the entire prostate should reduce normal tissue complications but still be effective in treating prostate cancer while the increased dose to the dominant lesion should improve tumour control. The use of only 5 fractions will reduce the number of patient visits, thus reducing overall treatment costs.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society